1. | EXECUTIVE SUMMARY AND CONCLUSIONS |
1.1. | Executive introduction |
1.2. | Executive introduction |
1.3. | Introduction to diabetes |
1.4. | The cost of diabetes |
1.5. | Blood glucose management basics |
1.6. | Diabetes management device roadmap: Summary |
1.7. | Diabetes management device roadmap: Glucose sensors |
1.8. | Blood glucose monitoring test strips and associated readers |
1.9. | Continuous glucose monitoring |
1.10. | Focus shifts from glucose test strips to CGMs |
1.11. | When will non-invasive glucose monitoring be commercialized? |
1.12. | Diabetes management device roadmap: Insulin delivery |
1.13. | Insulin pens |
1.14. | Insulin pumps |
1.15. | Introduction to automated insulin delivery (AID) systems |
1.16. | Closing the loop will drive further insulin pump uptake |
1.17. | Digital health is at the core of diabetes management |
1.18. | Diabetes device industry market forecast 2025-2035 |
1.19. | Diabetes device industry market forecast 2025-2035: Discussion |
1.20. | Access More With an IDTechEx Subscription |
2. | INTRODUCTION |
2.1.1. | Introduction to diabetes |
2.1.2. | Diabetes is on the rise |
2.1.3. | The cost of diabetes |
2.1.4. | Type 1 Diabetes vs Type 2 Diabetes |
2.1.5. | Blood glucose levels: Hyperglycemia and hypoglycemia |
2.1.6. | Medical devices for diabetes self management |
2.1.7. | Diabetes management device roadmap: Summary |
2.1.8. | Diabetes management device roadmap: Glucose sensors |
2.1.9. | Diabetes management device roadmap: Insulin delivery |
2.2. | Introduction to Key Diabetes Management Players |
2.2.1. | Key diabetes management companies covered in this report |
2.2.2. | Roche Diabetes Care |
2.2.3. | Abbott Diabetes Care |
2.2.4. | Dexcom |
2.2.5. | Medtronic Diabetes Operating Unit |
2.2.6. | Novo Nordisk Diabetes Care |
2.2.7. | Insulet |
3. | GLUCOSE SENSORS |
3.1. | Introduction to Glucose Sensors |
3.1.1. | History of glucose monitoring |
3.1.2. | History of glucose monitoring |
3.1.3. | Glucose monitoring: Key players |
3.1.4. | Diabetes management device roadmap: Glucose sensors |
3.1.5. | Key criteria for assessing accuracy |
3.1.6. | Glucose oxidase: Introduction |
3.1.7. | Glucose oxidase: Mechanism |
3.1.8. | Glucose dehydrogenase: Introduction |
3.1.9. | Glucose dehydrogenase: Mechanism and mediators |
3.1.10. | Glucose dehydrogenase vs glucose oxidase |
3.1.11. | Glucose dehydrogenase vs glucose oxidase: Advantages and disadvantages |
3.1.12. | The generations of glucose sensors |
3.1.13. | The generations of glucose sensors |
3.1.14. | The generations of glucose sensors: Advantages and disadvantages |
3.2. | Self-Monitoring Blood Glucose: Glucose Test Strips |
3.2.1. | Blood glucose monitoring test strips and associated readers |
3.2.2. | Anatomy of a glucose test strip |
3.2.3. | Electrode deposition: Screen printing vs sputtering |
3.2.4. | Companies utilize multiple manufacturing methods |
3.2.5. | Innovation shifts from test strip development to increasing digitalization |
3.3. | Self-Monitoring Blood Glucose: Market and Key Players |
3.3.1. | Blood glucose monitoring: Business model |
3.3.2. | Blood glucose monitoring: Market share |
3.3.3. | Roche Diabetes Care: Accu-Chek |
3.3.4. | Roche Diabetes Care: SMBG revenue |
3.3.5. | Abbott Diabetes Care: FreeStyle Optium |
3.3.6. | LifeScan: OneTouch |
3.3.7. | Challenges to the blood glucose monitoring market |
3.3.8. | Cost of glucose test strips vs continuous glucose monitors |
3.3.9. | Glucose test strips: Market outlook |
3.4. | Continuous Glucose Monitoring (CGM) |
3.4.1. | Continuous glucose monitoring |
3.4.2. | Benefits of continuous glucose monitoring |
3.4.3. | Anatomy of a typical CGM device |
3.4.4. | CGM technology |
3.4.5. | CGM sensor chemistry: Abbott, Dexcom, Medtronic |
3.4.6. | CGM sensor chemistry: Fluorescence-based glucose sensing |
3.4.7. | CGM sensor anatomy and manufacturing |
3.4.8. | CGM sensor filament structure |
3.4.9. | Implantable glucose sensors |
3.4.10. | Foreign body response to CGM devices |
3.4.11. | CGMs move to factory calibration |
3.4.12. | Comparison of recently launched CGM devices |
3.4.13. | Accuracy of CGM devices over time |
3.4.14. | Interference of medication with CGM accuracy |
3.4.15. | Predictive glucose and the potential for artificial intelligence |
3.5. | Continuous Glucose Monitoring: Market and Key Players |
3.5.1. | Focus shifts from glucose test strips to CGMs |
3.5.2. | CGM: overview of key players |
3.5.3. | Abbott Diabetes Care: FreeStyle Libre |
3.5.4. | Abbott Diabetes Care: Wired enzyme technology |
3.5.5. | Abbott Diabetes Care: Sensor structure |
3.5.6. | Dexcom: G6 & G7 |
3.5.7. | Dexcom: ONE, ONE+, Stelo |
3.5.8. | Senseonics: Eversense |
3.5.9. | Senseonics: Sensor technology |
3.5.10. | Implantable CGMs |
3.5.11. | Reimbursement of CGM technologies grows |
3.5.12. | CGM markets in Asia |
3.5.13. | New entrants in the CGM market |
3.5.14. | Clinician concern for CGMs in type 2 diabetes |
3.5.15. | Reimbursement for type 2 diabetes is currently limited |
3.5.16. | Direct to consumer CGMs for T2D and wellness |
3.5.17. | CGM in hospitals |
3.5.18. | CGM: market outlook |
3.6. | Non-Invasive Glucose Monitoring Technology |
3.6.1. | Non-invasive glucose monitoring |
3.6.2. | In context: FDA requirements for blood glucose monitoring |
3.6.3. | FDA safety communication on non-invasive smart watches |
3.6.4. | Non-invasive techniques for blood and interstitial glucose |
3.6.5. | Summary of non-invasive glucose sensing techniques |
3.6.6. | Near-infrared (NIR) and short-wave infrared (SWIR) spectroscopy |
3.6.7. | Mid-infrared spectroscopy |
3.6.8. | Raman spectroscopy |
3.6.9. | Optical rotation |
3.6.10. | Dielectric spectroscopy |
3.6.11. | Transdermal techniques |
3.6.12. | Reverse iontophoresis |
3.6.13. | Assessment of different analytes for non-invasive glucose monitoring |
3.6.14. | Measuring glucose in sweat |
3.6.15. | Measuring glucose in tears |
3.6.16. | Measuring glucose in saliva |
3.6.17. | Measuring glucose in breath |
3.6.18. | Measuring glucose in urine |
3.6.19. | When will non-invasive glucose monitoring be commercialized? |
3.6.20. | Non-invasive glucose sensing techniques: Company landscape |
4. | INSULIN DELIVERY |
4.1. | Introduction to Insulin Delivery |
4.1.1. | Insulin |
4.1.2. | Delivering insulin is a critical part of diabetes management |
4.1.3. | Types of insulin and their use cases |
4.1.4. | Comparison of different types of insulin |
4.1.5. | Short-acting (bolus) insulin |
4.1.6. | Long-acting (basal) insulin |
4.1.7. | Diabetes management device roadmap: Insulin delivery |
4.2. | Insulin Pens |
4.2.1. | Insulin pens |
4.2.2. | Smarter insulin delivery informing decisions |
4.2.3. | Smart insulin pen: Essential functions |
4.2.4. | Growing digital health market drives smart pen uptake |
4.2.5. | Overview of commercial smart pen devices |
4.2.6. | Novo Nordisk: FlexPen, FlexTouch, NovoPen 6, & NovoPen Echo Plus |
4.2.7. | Outlook for insulin pens |
4.3. | Insulin Pumps |
4.3.1. | Insulin pumps |
4.3.2. | Insulin patch pumps |
4.3.3. | Insulin pump breakdown |
4.3.4. | Overview of commercial insulin pumps |
4.3.5. | Barriers to insulin pump adoption |
4.3.6. | Device security: Implications for insulin pumps |
4.4. | Insulin Pumps: Market and Key Players |
4.4.1. | Insulin pump market |
4.4.2. | Insulin pump market: Overview of key players |
4.4.3. | Technology innovations drive insulin pump market |
4.4.4. | The rise of the tubeless insulin pumps |
4.4.5. | Pricing models for patch pumps vs tethered pumps |
4.4.6. | Medtronic: MiniMed 780G |
4.4.7. | Insulet: Omnipod 5 |
4.4.8. | Insulet: Omnipod DASH, Omnipod GO |
4.4.9. | Insulin pumps: Market outlook |
4.5. | Alternative Insulin Technologies |
4.5.1. | Non-invasive insulin delivery methods |
4.5.2. | Assessment of different routes for non-invasive insulin delivery |
4.5.3. | Inhaled insulin: Introduction |
4.5.4. | Inhaled insulin: Commercial challenges |
4.5.5. | Oral insulin |
4.5.6. | Buccal insulin |
4.5.7. | Transdermal insulin |
4.5.8. | Non-invasive insulin: Barriers to market adoption |
4.5.9. | Glucose-responsive insulin |
4.5.10. | The poor track record in non-invasive insulin |
5. | TOWARDS CLOSED-LOOP SYSTEMS AND ARTIFICIAL PANCREAS |
5.1. | Introduction to automated insulin delivery (AID) systems |
5.2. | Insulin pump technology roadmap |
5.3. | Interoperability essential to new hybrid closed-loop systems |
5.4. | Advanced hybrid closed-loop |
5.5. | Model predictive control |
5.6. | PID control |
5.7. | Case study: Progress from Medtronic |
5.8. | Medtronic: SmartGuard and Meal Detection |
5.9. | Medtronic: SmartGuard and Meal Detection |
5.10. | Dexcom: Partnerships for hybrid-closed loop systems |
5.11. | Interoperable automated glycemic controllers (iAGCs) |
5.12. | Progress towards automated insulin delivery |
6. | DIGITAL HEALTH |
6.1. | Diabetes is an early adopter of digital healthcare initiatives |
6.2. | Diabetes digital health landscape |
6.3. | Diabetes management apps: Ecosystem |
6.4. | Diabetes management apps |
6.5. | Digital health and connected diabetes management hardware |
6.6. | CGM integration with mobile apps |
6.7. | Lifestyle management apps: Focal points |
6.8. | Diet management: Meal tracking and diet planning |
6.9. | Telehealth in diabetes: Introduction |
6.10. | Regulatory requirements: Telemedicine |
6.11. | Telehealth in Type 2 and pre-diabetes: Examples |
6.12. | Addressing prediabetes via digital health |
6.13. | Digital health programs: Evidence for type 2 diabetes |
6.14. | Digital health and diabetes: Outlook |
7. | ADVANCED THERAPIES FOR DIABETES |
7.1. | Diabetes management device roadmap: Advanced therapies |
7.2. | Advanced therapies: Introduction |
7.3. | Cell therapy devices for type 1 diabetes |
7.4. | Advanced therapies: Conclusions |
8. | TECHNOLOGIES FOR DIABETES COMPLICATIONS |
8.1. | Introduction |
8.1.1. | Managing side effects accounts for 90% of the total cost of diabetes |
8.2. | Diabetic Ketoacidosis |
8.2.1. | Diabetic ketoacidosis: Introduction |
8.2.2. | Ketone monitoring: Electrochemical sensors |
8.2.3. | Ketone monitoring: Urine test strips |
8.2.4. | Ketone monitoring: Outlook |
8.2.5. | Diabetic Neuropathy & Retinopathy |
8.2.6. | Diabetic neuropathy and diabetic foot ulcers |
8.2.7. | Diabetic foot ulcers: Smart footwear for monitoring |
8.2.8. | Diabetic retinopathy: Introduction |
8.2.9. | Diabetic retinopathy: AI image recognition software |
8.2.10. | Diabetic retinopathy: Wearable vision aids |
8.2.11. | Diabetic neuropathy and retinopathy: Outlook |
9. | MARKET FORECASTS |
9.1. | Introduction |
9.2. | Market sizing and forecast methodology |
9.3. | Diabetes device industry market forecast 2025-2035 |
9.4. | Diabetes device industry market forecast by proportion 2025-2035 |
9.5. | Diabetes device industry market forecast 2025-2035: Discussion |
9.6. | Self monitoring blood glucose market forecast 2025-2035 |
9.7. | Self monitoring blood glucose market forecast 2025-2035: Discussion |
9.8. | CGM market forecast 2025-2035 |
9.9. | CGM market forecast 2025-2035: Discussion |
9.10. | Insulin pen market forecast 2025-2035 |
9.11. | Insulin pump market forecast 2025-2035 |
9.12. | Insulin pump market forecast 2025-2035: Discussion |
9.13. | Tethered insulin pump market forecast 2025-2035 |
9.14. | Insulin patch pump market forecast 2025-2035 |
10. | COMPANY PROFILES |
10.1. | Abbott Diabetes Care |
10.2. | Abbott Diabetes Care update |
10.3. | AgaMatrix |
10.4. | Alpha Pharma |
10.5. | Artelus |
10.6. | Beta Bionics |
10.7. | Bionime |
10.8. | CamDiab |
10.9. | Carbometrics |
10.10. | CNOGA Medical |
10.11. | Dexcom |
10.12. | Dexcom update |
10.13. | DiabeLoop |
10.14. | Diabeloop update |
10.15. | DiaMonTech |
10.16. | Digital Diagnostics (formerly known as IDx) |
10.17. | Fitscript |
10.18. | Glooko |
10.19. | Glooko update |
10.20. | GlucoRx |
10.21. | GlucoRx (BioXensor) |
10.22. | i-Sens |
10.23. | Impeto Medical |
10.24. | Infinovo |
10.25. | Inreda Diabetic |
10.26. | Insulet |
10.27. | Kriya Therapeutics |
10.28. | MannKind |
10.29. | Medtronic (Diabetes Division) |
10.30. | Medtronic Diabetes |
10.31. | Medtrum Technologies |
10.32. | National Diagnostic Products |
10.33. | Nemaura Medical |
10.34. | Orpyx |
10.35. | PKvitality |
10.36. | PKVitality update |
10.37. | Quantum Operation |
10.38. | RSP Systems |
10.39. | RSP Systems update |
10.40. | Senseonics |
10.41. | Siren Care Denmark |
10.42. | SNAQ |
10.43. | SOOIL Development |
10.44. | TaiDoc |
10.45. | Tidepool |
10.46. | Welldoc: Diabetes |